Related Experiment Video
Updated: Oct 18, 2025

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
Crosstalk between Heart Failure and Cognitive Impairment via hsa-miR-933/RELB/CCL21 Pathway
Wenxiao Feng1,2, Jie Yang3, Wenchao Song4
1First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Shandong, China.
Insights
This study explored the link between heart failure (HF) and cognitive impairment using bioinformatics. It identified a potential hsa-miR-933/RELB/CCL21 pathway involved in both conditions.
Area of Science:
- Biomedical Informatics
- Molecular Biology
- Cardiology
Background:
- Growing interest in the association between heart failure (HF) and cognitive impairment.
- Lack of systematic studies on the role of microRNAs (miRNAs) in the crosstalk between HF and cognitive impairment.
Purpose of the Study:
- To investigate the molecular mechanisms underlying the crosstalk between HF and cognitive impairment.
- To identify potential biomarkers for cognitive impairment prediction in HF patients.
Main Methods:
- Downloaded RNA-seq and clinical data from the Gene Expression Omnibus (GEO) database.
- Utilized R software for statistical analysis to identify differentially expressed miRNAs (DE-miRNAs) and mRNAs (DE-mRNAs).
- Constructed protein-protein interaction (PPI) networks and developed a logistic regression model for cognitive impairment prediction.
Main Results:
- Identified DE-miRNAs and DE-mRNAs common to both HF and cognitive impairment.
- Validated a logistic regression model based on DE-miRNAs for effective cognitive impairment prediction.
- Established a core miRNA-transcription factor (TF)-mRNA regulatory pathway, highlighting hsa-miR-933/RELB/CCL21 as a key axis.
Conclusions:
- This study represents the first bioinformatics approach to elucidate the crosstalk between HF and cognitive impairment.
- The findings suggest a significant regulatory role of the hsa-miR-933/RELB/CCL21 axis in HF and cognitive impairment.
- The identified pathway offers potential therapeutic targets for neurological disorders associated with HF.
Background:
The association between heart failure (HF) and cognitive impairment has received increasing attention from scholars and researchers in recent years. However, no systematic studies have been carried out yet focused on the crosstalk between heart failure and cognitive impairment via miRNAs.
Methods:
GSE104150, GSE53473, GSE120584, and GSE116250 with RNA-seq data and clinical data were downloaded from the GSE database. All data were statistically analysed using R software to detect DE-miRNAs and DE-mRNAs associated with both HF and cognitive impairment. Protein-protein interaction (PPI) networks were mapped, and a logistic regression model for cognitive impairment prediction was developed. Furthermore, the TTRUST database and miRWalk were used to map miRNA-transcription factor (TF) and messenger RNA (mRNA) regulatory pathways. Finally, core TFs were enriched for analysis.
Results:
Differentially enriched DE-miRNAs and DE-mRNAs both present in HF and cognitive impairment were determined. A logistic regression model established based on DE-miRNAs was validated to have a strong performance in cognitive impairment prediction. The core miRNA-TF-mRNA pathway was formed by mapping the PPI networks associated with the two diseases. Further GSEA was performed with V-rel reticuloendotheliosis viral oncogene homolog B (RELB) as the core TF, and the retinol metabolism and gap junction pathways were analysed.
Conclusions:
This study was the first attempt to predict the crosstalk and examine underlying mechanisms between HF and cognitive impairment applying bioinformatics. The findings suggested a potential hsa-miR-933/RELB/CCL21 regulatory axis correlated with HF and neurological disorders (or cognitive impairment), according to PPI networks.
Related Concept Videos
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure III: Clinical Manifestations
Heart Failure I: Introduction
Heart Failure V: Medical Management

